MVP and Daiichi Signs Exclusive Distribution and License Agreement for Penthrox in China, Thailand, Vietnam

 MVP and Daiichi Signs Exclusive Distribution and License Agreement for Penthrox in China, Thailand, Vietnam

MVP and Daiichi Signs Exclusive Distribution and License Agreement for Penthrox in China, Thailand, Vietnam

Shots:

  • Medical Developments International (MVP) to receive up to $32.5M (AUD $45.8M) as total deal value plus $15M upfront and additional sales-based milestones payments
  • MVP will fund the regulatory process of Penthrox in China and both companies will jointly collaborate with Japan’s service provider, EPS International Holdings for its approval. MVP will hold the drug import license rights on approval of Penthrox
  • Penthrox is a non-opioid analgesic inhaler with fast-onset self-administered pain reliever. The agreement focuses on treatments for acute pain management in Chinese, Vietnamese and Thai markets

Click here to read full press release/ article | Ref: MVP | Image: MVP

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post